GlaxoSmithKline’s Arzerra Gets Better CLL Label, But Now Faces Competition With Gazyva
This article was originally published in The Pink Sheet Daily
GlaxoSmithKline exec Klaus Edvardsen says the new label should give drug a boost, as previous indication was very restrictive. Approved in 2009, Arzerra had just £75 million in 2013 worldwide sales.
You may also be interested in...
The U.K.’s NICE has given the nod to GSK’s Arzerra (ofatumumab) for first-line CLL, making an eventual rivalry with Roche’s Gazyvaro and potentially revived MabThera a possibility.
The market for chronic lymphocytic leukemia drugs is undergoing big changes, with three new drugs approved: Roche’s antibody Gazyva and two oral therapies from Pharmacyclics/J&J and Gilead. Side effect profiles, administration and progression-free survival rates are helping to guide treatment decisions.
WellPoint’s new oncology treatment pathway for CLL, released in September, will use higher payments to doctors to steer them to drugs it feels offer the best outcomes and value.